专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07884124B2 Fluoro-substituted inhibitors of D-amino acid oxidase 有权
标题翻译：氟取代的D-氨基酸氧化酶抑制剂
公开(公告)号：US07884124B2
公开(公告)日：2011-02-08
申请号：US11772798
申请日：2007-07-02
申请人： Michele L. R. Heffernan , Robert J. Foglesong , Seth C. Hopkins , Mustapha Soukri , Steven W. Jones , Kerry L. Spear , Mark A. Varney
发明人： Michele L. R. Heffernan , Robert J. Foglesong , Seth C. Hopkins , Mustapha Soukri , Steven W. Jones , Kerry L. Spear , Mark A. Varney
IPC分类号： A61K31/40 , C07D487/02 , C07D491/02 , C07D495/02 , C07D497/02
CPC分类号： C07D495/04 , C07D491/04
摘要： This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O−X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.
摘要翻译：本发明提供了D-氨基酸氧化酶酶的新型抑制剂以及包含本发明化合物的药物组合物。本发明还提供了治疗和预防神经系统疾病如神经精神和神经退行性疾病以及疼痛，共济失调和惊厥的方法。本发明的化合物具有以下通式：其中A是NH或S.Q是选自CR1和N的成员.X和Y是独立地选自O，S，CR2，N和NH的成员。 R 1，R 2和R 4是独立地选自H和F的成员，条件是选自R 1，R 2和R 4中的至少一个是F.R 6是选自O-X +和OH的成员，其中X +是正离子，其中是选自无机正离子和有机正离子的成员。

2. 发明授权

US08669291B2 Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors 有权
标题翻译：苯基取代的环烷基胺作为单胺再摄取抑制剂
公开(公告)号：US08669291B2
公开(公告)日：2014-03-11
申请号：US12131845
申请日：2008-06-02
申请人： Liming Shao , Fengjiang Wang , Scott Christopher Malcolm , Michael Charles Hewitt , Jianguo Ma , Seth Ribe , Mark A. Varney , Una Campbell , Sharon Rae Engel , Larry Wendell Hardy , Patrick Koch , Rudy Schreiber , Kerry L. Spear
发明人： Liming Shao , Fengjiang Wang , Scott Christopher Malcolm , Michael Charles Hewitt , Jianguo Ma , Seth Ribe , Mark A. Varney , Una Campbell , Sharon Rae Engel , Larry Wendell Hardy , Patrick Koch , Rudy Schreiber , Kerry L. Spear
IPC分类号： A61K31/133 , A61K31/135 , C07C211/17
CPC分类号： C07C215/42 , A61K31/135 , A61P25/24 , A61P25/28 , C07B2200/07 , C07C217/52 , C07C217/76 , C07C2601/14
摘要： Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
摘要翻译：公开了苯基取代的环己胺衍生物及其合成和表征的方法。本文阐述了这些化合物治疗/预防神经系统疾病及其合成方法的用途。本发明的示例性化合物抑制内源性单胺如多巴胺，5-羟色胺和去甲肾上腺素的再摄取（例如，从突触腭裂）并调节一种或多种单胺转运蛋白。还提供了掺入本发明化合物的药物制剂。

3. 发明申请

US20090005456A1 PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS 有权
标题翻译：苯胺取代的环丙基胺作为单体反应抑制剂
公开(公告)号：US20090005456A1
公开(公告)日：2009-01-01
申请号：US12131845
申请日：2008-06-02
申请人： Liming Shao , Fengjiang Wang , Scott Christopher Malcolm , Michael Charles Hewitt , Jianguo Ma , Seth Ribe , Mark A. Varney , Una Campbell , Sharon Rae Engel , Larry Wendell Hardy , Patrick Koch , Rudy Schreiber , Kerry L. Spear
发明人： Liming Shao , Fengjiang Wang , Scott Christopher Malcolm , Michael Charles Hewitt , Jianguo Ma , Seth Ribe , Mark A. Varney , Una Campbell , Sharon Rae Engel , Larry Wendell Hardy , Patrick Koch , Rudy Schreiber , Kerry L. Spear
IPC分类号： A61K31/135 , C07C211/29 , A61P25/24 , A61P3/04 , A61P25/34
CPC分类号： C07C215/42 , A61K31/135 , A61P25/24 , A61P25/28 , C07B2200/07 , C07C217/52 , C07C217/76 , C07C2601/14
摘要： Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
摘要翻译：公开了苯基取代的环己胺衍生物及其合成和表征的方法。本文阐述了这些化合物治疗/预防神经系统疾病及其合成方法的用途。本发明的示例性化合物抑制内源性单胺如多巴胺，5-羟色胺和去甲肾上腺素的再摄取（例如，从突触腭裂）并调节一种或多种单胺转运蛋白。还提供了掺入本发明化合物的药物制剂。

4. 发明申请

US20080175903A1 Treatment of anxiety with eszopiclone 审中-公开
标题翻译：用佐佐匹克治疗焦虑症
公开(公告)号：US20080175903A1
公开(公告)日：2008-07-24
申请号：US11998839
申请日：2007-12-01
申请人： Seth C. Hopkins , Mark A. Varney , Tushar Misra , Gary Maier , Judy Caron , Randall S. Wagner
发明人： Seth C. Hopkins , Mark A. Varney , Tushar Misra , Gary Maier , Judy Caron , Randall S. Wagner
IPC分类号： A61K31/4985 , A61K9/54 , A61P25/22
CPC分类号： A61K31/4985
摘要： The present disclosure provides a unit dosage form with an anxiolytic dosage of zopiclone particularly eszopiclone. Also provided is a method for treatment or prophylaxis of anxiety using a subsedative dosage of zopiclone particularly eszopiclone.
摘要翻译：本公开提供具有抗焦虑剂量的佐匹克隆，特别是佐佐匹克的单位剂型。还提供了使用辅助剂量的佐匹克隆特别是佐佐匹克来治疗或预防焦虑的方法。

5. 发明申请

US20100190861A1 CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS 有权
标题翻译：环丙基胺作为单胺类复制抑制剂
公开(公告)号：US20100190861A1
公开(公告)日：2010-07-29
申请号：US12688474
申请日：2010-01-15
申请人： Liming Shao , Fengjiang Wang , Scott Christopher Malcolm , Michael Charles Hewitt , Larry R. Bush , Jianguo Ma , Mark A. Varney , Una Campbell , Sharon Rae Engel , Larry Wendell Hardy , Patrick Koch , John E. Campbell
发明人： Liming Shao , Fengjiang Wang , Scott Christopher Malcolm , Michael Charles Hewitt , Larry R. Bush , Jianguo Ma , Mark A. Varney , Una Campbell , Sharon Rae Engel , Larry Wendell Hardy , Patrick Koch , John E. Campbell
IPC分类号： A61K31/135 , C07C211/15 , C07C215/48 , A61P25/00 , A61P25/24
CPC分类号： C07D333/20 , C07C211/17 , C07C211/29 , C07C211/40 , C07C215/42 , C07C215/44 , C07C217/52 , C07C217/74 , C07C323/32 , C07C2601/02 , C07C2601/08 , C07C2601/10 , C07C2601/14 , C07C2601/16 , C07C2602/08 , C07D207/06 , C07D207/08 , C07D211/14 , C07D211/16 , C07D265/14 , C07D277/28 , C07D295/06 , C07D307/52 , C07D317/58 , C07D317/72 , C07D319/06 , C07D491/056
摘要： The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
摘要翻译：本发明涉及新的环己胺衍生物及其在治疗和/或预防中枢神经系统（CNS）障碍如抑郁，焦虑，精神分裂症和睡眠障碍中的用途及其合成方法。本发明还涉及含有本发明化合物的药物组合物，以及抑制内源性单胺如从突触间隙中再摄取多巴胺，5-羟色胺和去甲肾上腺素以及调节一种或多种单胺转运蛋白的方法。

6. 发明授权

US08053603B2 Tetralone-based monoamine reuptake inhibitors 有权
标题翻译：基于四氢萘酮的单胺再摄取抑制剂
公开(公告)号：US08053603B2
公开(公告)日：2011-11-08
申请号：US11643190
申请日：2006-12-21
申请人： Liming Shao , Fengjiang Wang , Scott Christopher Malcolm , Michael Charles Hewitt , Larry R. Bush , Mark A. Varney , Una Campbell , Sharon Rae Engel , Larry Wendell Hardy , Patrick Koch , Jianguo Ma
发明人： Liming Shao , Fengjiang Wang , Scott Christopher Malcolm , Michael Charles Hewitt , Larry R. Bush , Mark A. Varney , Una Campbell , Sharon Rae Engel , Larry Wendell Hardy , Patrick Koch , Jianguo Ma
IPC分类号： C07C211/42 , A61K31/133 , A61K31/135
CPC分类号： C07C211/40 , C07C17/16 , C07C17/35 , C07C45/38 , C07C45/52 , C07C45/63 , C07C45/67 , C07C45/68 , C07C45/74 , C07C211/29 , C07C211/30 , C07C211/42 , C07C215/44 , C07C217/74 , C07C2601/14 , C07C2602/10 , C07D215/12 , C07C25/22 , C07C22/04 , C07C47/453 , C07C49/67 , C07C49/697 , C07C49/255 , C07C49/755 , C07C49/683
摘要： The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods of inhibiting reuptake of one or more monoamine, such as such as dopamine and norepinephrine, from the synaptic cleft, and methods of modulating one or more monoamine transporter.
摘要翻译：本发明涉及新的四氢萘酮类胺及其用于治疗中枢神经系统（CNS）障碍，例如抑郁症，注意缺陷多动障碍（ADHD）和帕金森病。本发明还涉及含有本发明化合物和组合物的药物组合物以及抑制一种或多种单胺（例如多巴胺和去甲肾上腺素）从突触裂缝再摄取的方法，以及调节一种或多种单胺转运蛋白的方法。

7. 发明申请

US20090111817A1 Combinations of Eszopiclone and an Antidepressant 审中-公开
标题翻译：依曲普洛酮和抗抑郁药的组合
公开(公告)号：US20090111817A1
公开(公告)日：2009-04-30
申请号：US11994647
申请日：2006-07-05
申请人： Judy Caron , Thomas Wessel , Karim Lalji , Mark A. Varney
发明人： Judy Caron , Thomas Wessel , Karim Lalji , Mark A. Varney
IPC分类号： A61K31/4985
CPC分类号： A61K31/4985 , A61K31/343 , A61K31/381 , A61K31/4745 , A61K45/06 , A61K2300/00
摘要： One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is an antidepressant. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
摘要翻译：本发明的一个方面涉及含有两种或更多种活性剂的药物组合物，所述活性剂当一起用于治疗例如更年期，情绪障碍，焦虑障碍或认知障碍时。药物组合物的第一组分是镇静剂佐佐匹克。药物组合物的第二组分是抗抑郁药。本发明还涉及治疗绝经，围绝经期，情绪障碍，焦虑障碍和认知障碍的方法。

8. 发明申请

US20120123164A1 Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders 有权
标题翻译：依佐匹克隆和反式4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺或反式4-（3,4-二氯苯基）-1,2,3， 4-四氢-1-萘胺，以及更年期和心情，焦虑和认知障碍的治疗方法
公开(公告)号：US20120123164A1
公开(公告)日：2012-05-17
申请号：US13358155
申请日：2012-01-25
申请人： Judy CARON , Thomas Wessel , Karim Lalji , Mark A. Varney , Roger P. Bakale , Surendra P. Singh , H. Scott Wilkinson , Xiping Su , Zhengxu Steve Han , Stefan G. Koenig
发明人： Judy CARON , Thomas Wessel , Karim Lalji , Mark A. Varney , Roger P. Bakale , Surendra P. Singh , H. Scott Wilkinson , Xiping Su , Zhengxu Steve Han , Stefan G. Koenig
IPC分类号： C07C209/28
CPC分类号： A61K31/4985 , A61K31/135 , C07C211/42 , C07C2602/10 , A61K2300/00
摘要： One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
摘要翻译：本发明的一个方面涉及含有两种或更多种活性剂的药物组合物，所述活性剂当一起用于治疗例如更年期，情绪障碍，焦虑障碍或认知障碍时。药物组合物的第一组分是镇静剂佐佐匹克。药物组合物的第二组分是反式4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺或反式4-（3,4-二氯苯基） 2,3,4-四氢-1-萘胺。本发明还涉及治疗绝经，围绝经期，情绪障碍，焦虑障碍和认知障碍的方法。

9. 发明申请

US20080293726A1 Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders 审中-公开
标题翻译：依佐匹克隆和反式4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺或反式4-（3,4-二氯苯基）-1,2,3， 4-四氢-1-萘胺，以及更年期和心情，焦虑和认知障碍的治疗方法
公开(公告)号：US20080293726A1
公开(公告)日：2008-11-27
申请号：US11994644
申请日：2006-07-06
申请人： Judy Caron , Thomas Wessel , Karim Lalji , Mark A. Varney , Roger P. Bakale , Surendra P. Singh , H. Scott Wilkinson , Xiping Su , Zhengxu Steve Han , Stefan G. Koenig
发明人： Judy Caron , Thomas Wessel , Karim Lalji , Mark A. Varney , Roger P. Bakale , Surendra P. Singh , H. Scott Wilkinson , Xiping Su , Zhengxu Steve Han , Stefan G. Koenig
IPC分类号： A61K31/498 , C07C209/22 , A61P25/00
CPC分类号： A61K31/4985 , A61K31/135 , C07C211/42 , C07C2602/10 , A61K2300/00
摘要： One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., menopause, mood disorders, anxiety disorders, or cognitive disorders. The first component of the pharmaceutical composition is a sedative eszopiclone. The second component of the pharmaceutical composition is trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine. The present invention also relates to a method of treating menopause, perimenopause, mood disorders, anxiety disorders, and cognitive disorders.
摘要翻译：本发明的一个方面涉及含有两种或更多种活性剂的药物组合物，所述活性剂当一起用于治疗例如更年期，情绪障碍，焦虑障碍或认知障碍时。药物组合物的第一组分是镇静剂佐佐匹克。药物组合物的第二组分是反式4-（3,4-二氯苯基）-1,2,3,4-四氢-N-甲基-1-萘胺或反式4-（3,4-二氯苯基） 2,3,4-四氢-1-萘胺。本发明还涉及一种治疗绝经，围绝经期，情绪障碍，焦虑障碍和认知障碍的方法。

10. 发明授权

US06956049B1 Methods of modulating processes mediated by excitatory amino acid receptors 失效
标题翻译：调节由兴奋性氨基酸受体介导的过程的方法
公开(公告)号：US06956049B1
公开(公告)日：2005-10-18
申请号：US09387135
申请日：1999-08-31
申请人： Nicholas D. P. Cosford , Ian A. McDonald , Stephen D. Hess , Mark A. Varney
发明人： Nicholas D. P. Cosford , Ian A. McDonald , Stephen D. Hess , Mark A. Varney
IPC分类号： A61K31/425 , C07D277/00 , A51K31/425
CPC分类号： C07D277/22 , A61K31/425
摘要： In accordance with the present invention, there are provided methods of modulating the activity of excitatory amino acid receptors using a specifically defined class of heterocyclic compounds. In one embodiment, there are provided methods of modulating metabotropic glutamate receptors. The present invention also discloses methods of treating disease using heterocyclic compounds. Diseases contemplated include cerebral ischemia, chronic neurodegeneration, psychiatric disorders, schizophrenia, mood disorders, emotion disorders, disorders of extrapyramidal motor function, obesity, disorders of respiration, motor control and function, attention deficit disorders, concentration disorders, pain disorders, neurodegenerative disorders, epilepsy, convulsive disorders, eating disorders, sleep disorders, sexual disorders, circadian disorders, drug withdrawal, drug addiction, compulsive disorders, anxiety, panic disorders, depressive disorders, skin disorders, retinal ischemia, retinal degeneration, glaucoma, disorders associated with organ transplantation, asthma, ischemia and astrocytomas. The invention further discloses methods of preventing disease conditions related to diseases of the pulmonary system, diseases of the nervous system, diseases of the cardiovascular system, diseases of the gastrointestinal system, diseases of the endocrine system, diseases of the exocrine system, diseases of the skin, cancer and diseases of the ophthalmic system. The invention also discloses pharmaceutically acceptable salt forms of heterocyclic compounds.
摘要翻译：根据本发明，提供了使用特定限定类杂环化合物调节兴奋性氨基酸受体活性的方法。在一个实施方案中，提供了调节代谢型谷氨酸受体的方法。本发明还公开了使用杂环化合物治疗疾病的方法。预期的疾病包括脑缺血，慢性神经变性，精神疾病，精神分裂症，情绪障碍，情绪障碍，锥体外系运动功能障碍，肥胖症，呼吸障碍，运动控制和功能，注意力缺陷障碍，集中症，疼痛障碍，神经变性疾病，癫痫症，惊厥性疾病，进食障碍，睡眠障碍，性障碍，昼夜节律障碍，药物戒断，药物成瘾，强迫症，焦虑症，恐慌症，抑郁症，皮肤病症，视网膜缺血，视网膜变性，青光眼，器官移植相关疾病，哮喘，局部缺血和星形细胞瘤。本发明还公开了预防与肺系统疾病，神经系统疾病，心血管系统疾病，胃肠系统疾病，内分泌系统疾病，外分泌系统疾病，皮肤，癌症和眼科疾病。本发明还公开了药学上可接受的杂环化合物的盐形式。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式